Samuel Backenroth
Nessuna posizione attualmente
Patrimonio netto: 14 400 $ in data 30/04/2024
Profilo
Samuel I.
Backenroth is the founder of Orphion Therapeutics, Inc., DepYmed, Inc. He previously worked as the Chief Financial Officer at Vascular Biogenics Ltd.
and Notable Labs Ltd.
From 2010 to 2019, he held the position of CFO, Secretary & Principal Accounting Officer at Ohr Pharmaceutical, Inc. In 2019, he served as the Chief Financial Officer, Secretary & Treasurer at Neubase Therapeutics, Inc. and NeuBase Therapeutics, Inc. Mr. Backenroth obtained his undergraduate degree from Touro College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
0.17% | 31/03/2023 | 15 000 ( 0.17% ) | 14 400 $ | 30/04/2024 |
Precedenti posizioni note di Samuel Backenroth
Società | Posizione | Fine |
---|---|---|
NEUBASE THERAPEUTICS, INC. | Direttore Finanziario/CFO | 30/09/2021 |
Neubase Therapeutics, Inc. /Old/
Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Direttore Finanziario/CFO | 01/01/2021 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Direttore Finanziario/CFO | 01/01/2019 |
NOTABLE LABS, LTD. | Direttore Finanziario/CFO | - |
Formazione di Samuel Backenroth
Touro College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
NEUBASE THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Health Technology |
DepYmed, Inc.
DepYmed, Inc. BiotechnologyHealth Technology DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY. | Health Technology |
Neubase Therapeutics, Inc. /Old/
Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Health Technology |
Orphion Therapeutics, Inc.
Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter. | Health Technology |
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
- Borsa valori
- Insiders
- Samuel Backenroth